MCID: GST049
MIFTS: 49

Gastrointestinal System Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal System Cancer

MalaCards integrated aliases for Gastrointestinal System Cancer:

Name: Gastrointestinal System Cancer 12 15
Digestive System Neoplasms 43 71
Gastrointestinal Neoplasms 43 71
Malignant Neoplasm of Gastrointestinal Tract 71
Gastrointestinal Tract Cancer 12
Digestive System Carcinoma 17
Cancer of Digestive System 71
Digestive System Neoplasm 17
Digestive System Cancer 12
Gi Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3119
ICD9CM 34 239.0
NCIt 49 C3052 C4890
ICD10 32 C26.9
UMLS 71 C0012243 C0017185 C0685938 more

Summaries for Gastrointestinal System Cancer

Disease Ontology : 12 An organ system cancer located in gastrointestinal tract that is manifested in organs of the gastrointestinal system.

MalaCards based summary : Gastrointestinal System Cancer, also known as digestive system neoplasms, is related to esophageal cancer and gastric cancer, and has symptoms including signs and symptoms, digestive An important gene associated with Gastrointestinal System Cancer is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs Celecoxib and parecoxib have been mentioned in the context of this disorder. Affiliated tissues include gastrointestinal tract, liver and testes.

Related Diseases for Gastrointestinal System Cancer

Diseases related to Gastrointestinal System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 esophageal cancer 33.6 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
2 gastric cancer 33.2 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
3 oral cavity cancer 33.1 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
4 pharynx cancer 33.1 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
5 hepatocellular carcinoma 31.8 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
6 pancreatic cancer 31.8 MIR31 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
7 gallbladder cancer 31.4 MIR145 MIR143 MALAT1 HOTAIR H19
8 lung cancer 31.4 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
9 lung cancer susceptibility 3 31.4 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
10 oral squamous cell carcinoma 31.2 MIR9-1 MIR31 MIR21 MIR199A1 MIR17 MIR145
11 ovarian cancer 31.2 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
12 colorectal cancer 31.2 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
13 lynch syndrome 31.2 MIR31 MIR17 H2AC18 APC
14 bladder cancer 31.2 MIR9-1 MIR31 MIR21 MIR199A1 MIR17 MIR145
15 gastrointestinal system disease 31.1 MIR9-1 MIR518A1 MIR31 MIR30A MIR21 MIR199A1
16 large intestine cancer 31.1 MIR9-1 MIR518A1 MIR31 MIR30A MIR21 MIR199A1
17 prostate cancer 31.1 MIR31 MIR30A MIR21 MIR199A1 MIR17 MIR145
18 rectum cancer 31.1 MIR518A1 MIR31 MIR21 MIR17 MIR145 MIR143
19 cholangiocarcinoma 31.1 MIR21 MALAT1 H19 APC
20 nasopharyngeal carcinoma 31.1 MIR9-1 MIR31 MIR30A MIR21 MIR17 MIR143
21 body mass index quantitative trait locus 11 31.1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR143
22 diffuse large b-cell lymphoma 31.1 MIR21 MIR199A1 MIR17 MIR145 MIR143 MIR126
23 melanoma 31.1 MIR31 MIR17 MIR122 MALAT1 HOTAIR H19
24 bile duct cancer 31.1 MIR9-1 MIR31 MIR21 MIR199A1 MIR17 MIR145
25 pancreatic ductal adenocarcinoma 31.1 MIR31 MIR21 MIR199A1 MIR196A1 MIR145 MIR143
26 intestinal benign neoplasm 31.0 MIR21 MIR199A1 MIR196A1 MIR17 MIR145 MIR143
27 pancreas disease 31.0 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
28 colorectal adenoma 31.0 MIR21 MIR17 APC
29 neuroblastoma 30.8 MIR21 MIR17 MIR125A MALAT1 HOTAIR H19
30 in situ carcinoma 30.8 MIR17 MIR143 MIR126 H2AC18
31 small cell cancer of the lung 30.7 MIR21 MALAT1 HOTAIR
32 anal canal carcinoma 11.1
33 gastrointestinal carcinoma 11.1
34 gastrointestinal neuroendocrine tumor 11.1
35 renal cell carcinoma, nonpapillary 11.0 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
36 squamous cell carcinoma, head and neck 11.0 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
37 myeloma, multiple 11.0 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
38 prostate disease 11.0 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
39 cervical cancer 11.0 MIR9-1 MIR31 MIR30A MIR21 MIR196A1 MIR17
40 reproductive system disease 11.0 MIR9-1 MIR518A1 MIR31 MIR30A MIR21 MIR199A1
41 leukemia, acute myeloid 11.0 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
42 nervous system disease 11.0 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
43 central nervous system disease 11.0 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
44 female reproductive system disease 11.0 MIR9-1 MIR518A1 MIR31 MIR30A MIR21 MIR199A1
45 colonic disease 11.0 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
46 cervix disease 11.0 MIR9-1 MIR518A1 MIR31 MIR30A MIR21 MIR199A1
47 intestinal disease 11.0 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
48 mouth disease 11.0 MIR9-1 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
49 hematologic cancer 11.0 MIR9-1 MIR518A1 MIR31 MIR30A MIR21 MIR199A1
50 male reproductive system disease 11.0 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1

Comorbidity relations with Gastrointestinal System Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Cholestasis Deficiency Anemia
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Gastrointestinal System Cancer:



Diseases related to Gastrointestinal System Cancer

Symptoms & Phenotypes for Gastrointestinal System Cancer

UMLS symptoms related to Gastrointestinal System Cancer:


signs and symptoms, digestive

Drugs & Therapeutics for Gastrointestinal System Cancer

Drugs for Gastrointestinal System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 293)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
parecoxib Approved Phase 4 198470-84-7
3
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
4
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
5
Zinc Approved, Investigational Phase 4 7440-66-6 32051
6
Insulin glargine Approved Phase 4 160337-95-1
7
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
8
Enoxaparin Approved Phase 4 9005-49-6 772
9
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
12
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
13
Racepinephrine Approved Phase 4 329-65-7 838
14
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
15 Analgesics, Non-Narcotic Phase 4
16 Cyclooxygenase Inhibitors Phase 4
17 Anti-Inflammatory Agents, Non-Steroidal Phase 4
18 Cyclooxygenase 2 Inhibitors Phase 4
19 Analgesics Phase 4
20 glutamine Phase 4
21 Anti-Arrhythmia Agents Phase 4
22 Insulin, Globin Zinc Phase 4
23 insulin Phase 4
24 Neuromuscular Blocking Agents Phase 4
25 Hypoglycemic Agents Phase 4
26 Anticonvulsants Phase 4
27 calcium channel blockers Phase 4
28 Tocolytic Agents Phase 4
29 Anticoagulants Phase 4
30 Antineoplastic Agents, Hormonal Phase 4
31 Antiemetics Phase 4
32 Hormone Antagonists Phase 4
33 Gastrointestinal Agents Phase 4
34 glucocorticoids Phase 4
35 BB 1101 Phase 4
36 Anti-Inflammatory Agents Phase 4
37 Respiratory System Agents Phase 4
38 Epinephryl borate Phase 4
39 Adrenergic Agents Phase 4
40 Adrenergic beta-Agonists Phase 4
41 Adrenergic alpha-Agonists Phase 4
42 Vasoconstrictor Agents Phase 4
43 Anti-Asthmatic Agents Phase 4
44 Adrenergic Agonists Phase 4
45 Bronchodilator Agents Phase 4
46 Sympathomimetics Phase 4
47 Mydriatics Phase 4
48 Anesthetics, Local Phase 4
49 Hemostatics Phase 4
50 Coagulants Phase 4

Interventional clinical trials:

(show top 50) (show all 463)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Unknown status NCT02860429 Phase 4 Cinobufacini injection;chemotherapy
2 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
3 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
4 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
5 A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate Completed NCT00793871 Phase 4 Sunitinib Malate (SU011248)
6 A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
7 Comparing With Traditional Nitrogen Calorie Parenteral Nutrition Support, the Impact of Low Calorie and Low Nitrogen Intake on the Clinical Outcome of Gastrointestinal Postoperative Patients, Multicentre Post-Marketing Clinical Study Completed NCT00247338 Phase 4 low calorie, low nitrogen parenteral nutrition for patient with NRS score 3
8 The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study Completed NCT01552291 Phase 4 Placebo
9 Assessment the Effect of Medium-Calorie TPN on Patients With Gastrointestinal Cancer Undergoing Surgery Completed NCT01700062 Phase 4
10 Muscle Relaxation During Open Upper Abdominal Surgery - Can the Surgical Conditions be Optimized? Completed NCT02140593 Phase 4 Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
11 Glargine Insulin Versus Continous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) Completed NCT02216799 Phase 4 Glargine Insulin;Regular insulin
12 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
13 Comparison of Thromboembolic Events in Patients Undergoing Gastrointestinal Cancer Surgery and Thromboprophylactic Treatment With Two Enoxaparin Formulations (ENOXA® vs Lovenox®) Recruiting NCT02444572 Phase 4 Enoxaparin 4000 IU
14 Efficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
15 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Active, not recruiting NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
16 Randomized Controlled Trial of Hemostatic Powder Versus Optimal Clinical Management for the Treatment of Upper Gastrointestinal Bleeding From Tumor Lesions Not yet recruiting NCT02820077 Phase 4
17 Clinical Trial on Ganoderma Spore Lipids Combined With Chemo in Patients With G.I. Cancers Unknown status NCT02785523 Phase 3 Ganoderma Spore Lipids;Placebo;Chemotherapy
18 A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Unknown status NCT03303495 Phase 3 CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
19 Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization for the Treatment of Colorectal Liver Metastases (SIM Trial) Unknown status NCT02208804 Phase 2, Phase 3
20 A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
21 Endoscopic Ultrasonography Guided Fine Needle Biopsy (EUS-FNB) vs. Single-incision Needle-knife (SINK) Biopsy for Diagnosis of Upper Gastrointestinal Subepithelial Lesions Unknown status NCT02866045 Phase 3
22 Peri-operative Usage of Enteric Immune-nutrition Formula (ANOM®) Versus Standard Formula for Patients Received Major Upper Gastrointestinal Surgery Unknown status NCT01351883 Phase 3
23 Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery Completed NCT00826410 Phase 3
24 A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer Completed NCT00486954 Phase 3 Lapatinib;Paclitaxel
25 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
26 A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Completed NCT01996306 Phase 3 CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);CPT-11 (Irinotecan);Capecitabine
27 A Clinical Randomized Control Trial of Combination TACE With and Without Low-molecular-weight Heparin in Hepatocellular Carcinoma Completed NCT00827554 Phase 2, Phase 3 LMWH
28 Randomized Trial Comparing Drainage Versus no Drainage Following Rectal Excision With Low Anastomosis for Rectal Cancer Completed NCT01269567 Phase 3
29 A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma Completed NCT00052962 Phase 3
30 Immunonutrition to Improve Quality of Life of Upper Gastrointestinal Cancer Patients Undergoing Oncological Treatment Completed NCT01423799 Phase 3
31 A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm Completed NCT02112656 Phase 3 ThermoDox;Dummy infusion
32 Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer: A Multicenter Randomized Clinical Trial Completed NCT02664974 Phase 3
33 Monosialotetrahexosylganglioside Sodium Injection for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
34 A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed NCT00513357 Phase 3 Melatonin;Placebo
35 A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Recruiting NCT03464305 Phase 3 acetylsalicylic acid;Placebo
36 Perioperative Chemotherapy With FOLFIRINOX Regimen or FLOT Regimen for Resectable Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial Recruiting NCT04393584 Phase 2, Phase 3 Irinotecan;5-FU;Leucovorin;Oxaliplatin;Docetaxel
37 A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer Recruiting NCT04163900 Phase 3 NUC-1031;Gemcitabine;Cisplatin
38 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
39 A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC). Active, not recruiting NCT02753127 Phase 3 Napabucasin;Fluorouracil;Leucovorin;Irinotecan;Bevacizumab
40 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel;Gemcitabine
41 A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
42 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
43 An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer Active, not recruiting NCT02322593 Phase 3 TAS-118 plus Oxaliplatin;S-1 plus Cisplatin
44 A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer Not yet recruiting NCT03889626 Phase 3 Apatinib;Capecitabine
45 An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) Terminated NCT01009593 Phase 3 ABT-869;Sorafenib
46 A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery Terminated NCT00254436 Phase 3 Procrit (epoetin alfa)
47 A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
48 Effect of 3 Day Pre-operative Immunonutrition Regimen on Clinical Outcome in Well-nourished Patients With Gastrointestinal Cancer Undergoing Surgery , a Randomised Double-blind Controlled Trial Terminated NCT01023412 Phase 3
49 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
50 A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients Terminated NCT00516269 Phase 3 Methylphenidate;Placebo

Search NIH Clinical Center for Gastrointestinal System Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Imatinib mesylate

Cochrane evidence based reviews: digestive system neoplasms

Genetic Tests for Gastrointestinal System Cancer

Anatomical Context for Gastrointestinal System Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Gastrointestinal System Cancer:

19
Gastrointestinal Tract

MalaCards organs/tissues related to Gastrointestinal System Cancer:

40
Liver, Testes, Colon, Lung, Breast, Pancreas, Lymph Node

Publications for Gastrointestinal System Cancer

Articles related to Gastrointestinal System Cancer:

(show top 50) (show all 428)
# Title Authors PMID Year
1
Small Bowel Gastrointestinal Stromal Tumor as a Gateway for Streptococcus anginosus Causing Multiple Liver Abscesses. 61
32494319 2020
2
Methods that Assist Traction during Endoscopic Submucosal Dissection of Superficial Gastrointestinal Cancers: A Systematic Literature Review. 61
31914722 2020
3
Endoscopic full-thickness resection of early colorectal neoplasms using an endoscopic submucosal dissection knife: a retrospective multicenter study. 61
32355878 2020
4
Targeted next-generation sequencing as a diagnostic tool in gastrointestinal system cancer/polyposis. 61
32390558 2020
5
The effect of scissor-type versus non-scissor-type knives on the technical outcomes in endoscopic submucosal dissection for superficial esophageal cancer: a multi-center retrospective study. 61
31617891 2020
6
Learning Curve for Endoscopic Submucosal Dissection With an Untutored, Prevalence-Based Approach in the United States. 61
31220645 2020
7
Hemorrhage control during gastric endoscopic submucosal dissection: Techniques using uncovered knives. 61
32055690 2020
8
Cathepsin S as a target in gastric cancer. 61
31929878 2020
9
A ruptured jejunal gastrointestinal stromal tumor with hemoperitoneum mimicking ovarian carcinoma. 61
32055272 2020
10
Efficacy of scissor-type knives for endoscopic mucosal dissection of superficial gastrointestinal neoplasms. 61
31120558 2020
11
Carcinoid Tumor: Advances in Treatment Options. 61
32064213 2020
12
Generation of magnifying endoscopic images of gastric neoplasms based on an all-in-focus algorithm. 61
31334881 2020
13
Predicting outcomes in colorectal endoscopic submucosal dissection: a United States experience. 61
30725255 2019
14
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. 61
31239549 2019
15
Feasibility of robotic resection of gastrointestinal stromal tumors along the entire gastrointestinal tract. 61
30019164 2019
16
An Epithelioid Gastrointestinal Stromal Tumor of the Stomach With Strong Expression of Keratin: Clinicopathologic Correlation and Follow-up Post-Imatinib Therapy. 61
28362703 2019
17
Correlation of molecular and morphological features of appendiceal epithelial neoplasms. 61
31111538 2019
18
Modular laser-based endoluminal ablation of the gastrointestinal tract: in vivo dose-effect evaluation and predictive numerical model. 61
30456508 2019
19
Early postoperative intraperitoneal chemotherapy for lower gastrointestinal neoplasms with peritoneal metastasis: a systematic review and critical analysis. 61
31667329 2019
20
"-Omas" presenting as "-itis": acute inflammatory presentations of common gastrointestinal neoplasms. 61
30719599 2019
21
Systematic review of anorectal leiomyosarcoma: Current challenges and recent advances. 61
31523383 2019
22
Efficacy and safety of steroid in the prevention of esophageal stricture after endoscopic submucosal dissection: A network meta-analysis. 61
30566746 2019
23
Short-term outcomes of traction-assisted versus conventional endoscopic submucosal dissection for superficial gastrointestinal neoplasms: a systematic review and meta-analysis of randomized controlled studies. 61
31164139 2019
24
Management of adverse events related to endoscopic resection of upper gastrointestinal neoplasms: Review of the literature and recommendations from experts. 61
30994225 2019
25
Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis. 61
30763436 2019
26
Identification of the critical viscoelastic factor in the performance of submucosal injection materials. 61
30423779 2019
27
Linked color imaging for the detection of early gastrointestinal neoplasms. 61
31700545 2019
28
Jejunal GIST: Hunting down an unusual cause of gastrointestinal bleed using double balloon enteroscopy. A case report. 61
31277041 2019
29
Pitfalls in the Interpretation of Publications about Endoscopic Submucosal Dissection of Early Gastric Cancer with Undifferentiated-Type Histology. 61
30650945 2019
30
The Four Horsemen in Colon Cancer. 61
31662752 2019
31
A Rare Case of a Ruptured Metastatic Hepatic Lesion from a Jejunal Gastrointestinal Stromal Tumor (GIST) Treated by Arterial Embolization. 61
30542049 2018
32
Organoid models of gastrointestinal Neoplasms: Origin, current status and future applications in personalized medicine. 61
30591933 2018
33
Ambient air pollution in gastrointestinal endoscopy unit; rationale and design of a prospective study. 61
30544484 2018
34
Switching from endoscopic submucosal dissection to salvage piecemeal knife-assisted snare resection to remove a lesion: A preoperative risk score from the beginning. 61
30221971 2018
35
Clinical Presentation of Gastrointestinal Stromal Tumors. 61
30498699 2018
36
Prognostic factors for death after surgery for small intestinal neuroendocrine tumours. 61
30263986 2018
37
Characteristic findings of high-grade cervical intraepithelial neoplasia or more on magnifying endoscopy with narrow band imaging. 61
29446041 2018
38
[Endoscopic techniques for early stage cancer of the upper and lower gastrointestinal tract : Possibilities and limitations]. 61
29188354 2018
39
A novel gel immersion technique using a bipolar needle-knife in endoscopic submucosal dissection for superficial gastrointestinal neoplasms. 61
29507476 2018
40
The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients. 61
29429533 2018
41
Development of a new ex vivo model for evaluation of endoscopic submucosal injection materials performance. 61
29329031 2018
42
Multiple neuroendocrine tumor of the small bowel: a case report and a review of literature. 61
30590945 2018
43
Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma. 61
29662529 2018
44
Gigantic GIST: A Case of the Largest Gastrointestinal Stromal Tumor Found to Date. 61
30363960 2018
45
Gastrointestinal malignant neoplasms disguised as pneumatosis cystoids intestinalis: A case report and literature review. 61
29390561 2017
46
Comparison of endoscopic ultrasonography and magnifying endoscopy for assessment of the invasion depth of shallow gastrointestinal neoplasms: a systematic review and meta-analysis. 61
28547665 2017
47
[Current status of hereditary gastrointestinal neoplasms]. 61
29178089 2017
48
Comparison of sedation between the endoscopy room and operation room during endoscopic submucosal dissection for neoplasms in the upper gastrointestinal tract. 61
29179691 2017
49
The effect of intraoperative hypothermia upon blood transfusion needs and length of stay among gastrointestinal system cancer surgery. 61
28417506 2017
50
[Duodenal leiomyoma - a rare case report]. 61
28876117 2017

Variations for Gastrointestinal System Cancer

Expression for Gastrointestinal System Cancer

Search GEO for disease gene expression data for Gastrointestinal System Cancer.

Pathways for Gastrointestinal System Cancer

Pathways related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR17
2 10.07 MIR199A1 MIR145

GO Terms for Gastrointestinal System Cancer

Cellular components related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 MIR31 MIR30A MIR21 MIR199A1 MIR17 MIR143
2 extracellular vesicle GO:1903561 9.1 MIR30A MIR21 MIR17 MIR126 MIR125A MIR122

Biological processes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.83 MIR21 MIR199A1 MIR143 MIR126
2 negative regulation of angiogenesis GO:0016525 9.76 MIR21 MIR145 MIR143 MIR125A
3 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.65 MIR21 MIR199A1 MIR145
4 positive regulation of angiogenesis GO:0045766 9.63 MIR31 MIR30A MIR21 MIR199A1 MIR143 MIR126
5 negative regulation of cardiac muscle hypertrophy GO:0010614 9.61 MIR21 MIR145
6 regulation of smooth muscle contraction GO:0006940 9.6 MIR145 MIR143
7 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.59 MIR199A1 MIR17
8 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.58 MIR21 MIR125A
9 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR199A1 MIR17
10 negative regulation of vascular endothelial growth factor production GO:1904046 9.58 MIR199A1 MIR17 MIR125A
11 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.57 MIR31 MIR125A
12 positive regulation of metalloendopeptidase activity GO:1904685 9.56 MIR21 MIR17
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.56 MIR31 MIR30A MIR143 MIR126
14 angiotensin-activated signaling pathway GO:0038166 9.55 MIR145 MIR143
15 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.54 MIR21 MIR17
16 positive regulation of sprouting angiogenesis GO:1903672 9.54 MIR31 MIR126 MIR125A
17 aorta smooth muscle tissue morphogenesis GO:0060414 9.51 MIR145 MIR143
18 regulation of phenotypic switching GO:1900239 9.49 MIR145 MIR143
19 gene silencing by miRNA GO:0035195 9.47 MIR9-1 MIR518A1 MIR31 MIR30A MIR21 MIR199A1
20 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.43 MIR17 MIR143
21 miRNA mediated inhibition of translation GO:0035278 9.43 MIR9-1 MIR31 MIR30A MIR21 MIR17 MIR145
22 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.32 MIR145 MIR143

Molecular functions related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR9-1 MIR518A1 MIR31 MIR30A MIR21 MIR199A1
2 RNA polymerase II complex binding GO:0000993 9.13 MIR145 MIR126 MIR125A

Sources for Gastrointestinal System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....